Boston Medical Sciences Co., Ltd. is pleased to announce that it has raised 930 million yen in a Series A round with new investors including JIC Venture Growth Investments Co., Ltd., Global Brain Corporation, Meiji Yasuda Life Insurance Company, Takanawa Earth Benefit Fund with East Japan Railway Company as the lead limited partner, Mitsubishi UFJ Capital Co., Ltd., Eukaria Co., Ltd., and Regional Healthcare Collaboration Platform Co., Ltd., in addition to existing investor Beyond Next Ventures Co., Ltd.
Founded in April 2023 by a doctor who serves as a faculty member and researcher at Harvard Medical School and Massachusetts General Hospital, the company aims to be the first in the world to clinically implement “AIM4CRC,” a laxative-free virtual endoscopy system, in Japan, with a background of strong technology and experience in AI research and development, medical image analysis, and clinical medicine. The funds raised this time will be used to further strengthen the research and development system, conduct upcoming domestic clinical trials, respond to pharmaceutical affairs in Japan and the United States, and expand the system with an eye toward market expansion.
Also Read: KEAN Health Launches AI Search for Genetic Testing with chatGENE Pro
To date, our company has achieved accelerated growth, including being selected for the “Deep Tech Startup Support Project” by the New Energy and Industrial Technology Development Organization (NEDO), the “Priority Review for Programmed Medical Devices (Priority SaMD)” by the Ministry of Health, Labor and Welfare, and the “HealthTech Gateway “AI Medical in the US”” provided by Mayo Clinic and the Japan External Trade Organization (JETRO). All employees will work together to achieve our company’s philosophy of “eradicating colorectal cancer deaths from the world through the power of early detection and prevention” as soon as possible.
SOURCE: PRTimes
